ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T-Regulatory Cells"

  • Abstract Number: 1643 • 2013 ACR/ARHP Annual Meeting

    Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg

    Gali Malul1, David Soler2, Donald D. Anthony3, Hillard M. Lazarus4, Nicholas Lehman5, Thomas McCormick2, Julia M. Sugalski6, Anthony E. Ting5 and Nora G. Singer7, 1Rheumatology, MetroHealth Medical Center, Cleveland, OH, 2Dermatology, Case Medical Center, Cleveland, OH, 3Medicine, Case Western Reserve University, Cleveland, OH, 4Comprehensive Cancer Center, Case Medical Center, Cleveland, OH, 5Athersys, Inc., Cleveland, OH, 6Medicine/infectious disease, Case Western Reserve University, Cleveland, OH, 7Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH

    Background/Purpose: Use of mesenchymal/multipotent stem cells (MSCs/MAPCs) is an emerging immune modulatory therapeutic strategy promising for a number of human diseases. Multipotent adult progenitor cells…
  • Abstract Number: 1641 • 2013 ACR/ARHP Annual Meeting

    Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B

    Stefanie Koristka1, Marc Cartellieri2, Claudia Arndt2, Anja Feldmann2, Irene Michalk2, Claudia C. Bippes2, Nicole Berndt2, Anne Hermsdorf2, Slava Stamova2, Biji T. Kurien3, Robert Hal Scofield4, A. Darise Farris5, Judith A. James6, Holger Bartsch7 and Michael Bachmann2, 1Carl Gustav Carus TU-Dresden, Dresden, Germany, 2Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, 3College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 5Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany

    Background/Purpose: Adoptive transfer of regulatory T cells (Tregs)  represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically…
  • Abstract Number: 1412 • 2013 ACR/ARHP Annual Meeting

    Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis

    Eva Dokoupilova1, Slawomir Jeka2, Jiri Vencovsky3, Janusz Badurski4, Klaas Prins5, Vibeke Strand6, Edward C. Keystone7, Ronald F van Vollenhoven8, Jurgen Wollenhaupt9, Andrea Wartenberg-Demand10, Gabriele Niemann10, Ahmed Abufarag10, Silke Aigner10, Sibylle Kaiser10, Faiza Rharbaoui10, Niklas Czeloth11, Ralf Wolter10, Benjamin Dälken10 and Thorsten Holzkämper10, 1Medical Plus s.r.o, Uherske Hradiste, Czech Republic, 2Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, 3Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 4Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, 5qPharmetra, Nijmegen, Netherlands, 6Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, 7Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 8ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 9Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 10Biotest AG, Dreieich, Germany, 11Global Research Immunology, Biotest AG, Dreieich, Germany

    Background/Purpose: In patients with rheumatoid arthritis (RA) reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed. Tregalizumab is a humanized, agonistic…
  • Abstract Number: 719 • 2013 ACR/ARHP Annual Meeting

    Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)

    Hiroshi Kato1 and Andras Perl2, 1Internal Medicine, Division of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, 2Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: mTOR activity is increased in SLE T cells and its blockade has therapeutic efficacy in SLE. Murine studies showed essential roles of mTORC1 in…
  • Abstract Number: 665 • 2013 ACR/ARHP Annual Meeting

    DNA hypermethylation of Forkhead box protein 3 (FOXP3) locus leads to quantitative defects of regulatory T cells in systemic sclerosis

    Yaoyao Wang1, Ye Shu2, Qing Wang1, Ming Zhao1, Gongping Liang1, Qianjin Lu1 and Rong Xiao1, 1Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, 2Department of Dermatology, Hunan Children's Hospital, Changsha, China

    Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of which the etiology and pathogenesis remains complex and poorly understood.  Attention has recently been directed…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology